|
Siegfried AG / Key word(s): Miscellaneous 04-Sep-2024 / 06:30 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. EGS Beteiligungen AG exercised its right to convert also the second of the two convertible bonds issued in December 2020 with a coupon of 1.15% and a nominal value of CHF 40m into shares of Siegfried Holding AG. EGS Beteiligungen AG will receive 48’054 shares and as a result will increase its stake in Siegfried from 6.2% to about 7.2% registered shares. The shares will be delivered from Siegfried’s treasury shares without issuance of new shares. As announced in December 2020, EGS Beteiligungen AG participated in the financing of Siegfried’s acquisition of two pharmaceutical production sites in Spain through two hybrid convertible bonds issued by Siegfried. These bonds granted EGS Beteiligungen AG the right to convert the bonds into shares of Siegfried Holding AG when certain conditions are met. Siegfried’s CEO Marcel Imwinkelried: “The increase in the shareholding of EGS Beteiligungen AG through this conversion reflects the confidence of our largest shareholder in our business model and strategy.”
About Siegfried The Siegfried Group is a global life sciences company with sites in Switzerland, Germany, Spain, France, Malta, the USA and China. In 2023, the company achieved sales of CHF 1.272 billion and employed on 31.12.2023 more than 3’700 people at twelve sites on three continents. Siegfried Holding AG is publicly listed on SIX Swiss Exchange (SIX: SFZN). Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, cartridges and ointments) for the pharmaceutical industry and provides development services. Cautionary Statements Regarding Forward-Looking Statements This media release includes statements concerning the future. They are based on assumptions and expectations that may prove to be wrong. They should be considered with due caution as, by definition, they contain known and unknown risks, insecurities and other factors which could result in a difference in the actual results, financial situation, developments or the success of Siegfried Holding AG or Siegfried Group from the explicit or implicit assumptions made in these statements. End of Inside Information |
Three women sue cancer diagnostic firm Grail alleging harassment, retaliation
Three sales executives, all of them women, have filed suit against Grail, a cancer diagnostics company, alleging that they were harassed, that the company failed
July 14, 2023